GNCA vs. HTGMQ, KLDO, UTRS, VIVE, ONCSQ, AHPI, VRAYQ, NOVNQ, HGEN, and ALVO
Should you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include HTG Molecular Diagnostics (HTGMQ), Kaleido Biosciences (KLDO), Minerva Surgical (UTRS), Viveve Medical (VIVE), OncoSec Medical (ONCSQ), Allied Healthcare Products (AHPI), ViewRay (VRAYQ), NVN Liquidation (NOVNQ), Humanigen (HGEN), and Alvotech (ALVO). These companies are all part of the "medical" sector.
Genocea Biosciences (NASDAQ:GNCA) and HTG Molecular Diagnostics (NASDAQ:HTGMQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, community ranking, dividends and analyst recommendations.
Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500. Comparatively, HTG Molecular Diagnostics has a beta of 2.73, meaning that its stock price is 173% more volatile than the S&P 500.
In the previous week, Genocea Biosciences had 2 more articles in the media than HTG Molecular Diagnostics. MarketBeat recorded 2 mentions for Genocea Biosciences and 0 mentions for HTG Molecular Diagnostics. Genocea Biosciences' average media sentiment score of 0.00 equaled HTG Molecular Diagnostics'average media sentiment score.
Genocea Biosciences received 388 more outperform votes than HTG Molecular Diagnostics when rated by MarketBeat users.
0.6% of Genocea Biosciences shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 2.6% of HTG Molecular Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
HTG Molecular Diagnostics' return on equity of 0.00% beat Genocea Biosciences' return on equity.
HTG Molecular Diagnostics has higher revenue and earnings than Genocea Biosciences.
Summary
HTG Molecular Diagnostics beats Genocea Biosciences on 6 of the 9 factors compared between the two stocks.
Get Genocea Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genocea Biosciences Competitors List
Related Companies and Tools
